ANIP - ANI Pharmaceuticals Inc
IEX Last Trade
63.83
1.380 2.162%
Share volume: 365,554
Last Updated: Fri 30 Aug 2024 09:59:54 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$62.45
1.38
2.21%
View ratios
Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
Report Date | 2022-05-10 | 2022-08-08 | 2022-11-09 | 2023-03-09 | 2023-05-08 | 2023-08-09 | 2023-11-08 | 2024-02-29 | |
Assets | |||||||||
Total Assets | 744.846 M | 751.334 M | 739.110 M | 760.087 M | 765.224 M | 859.341 M | 889.914 M | 904.422 M | |
Current Assets | 301.399 M | 322.399 M | 309.377 M | 344.261 M | 364.753 M | 459.311 M | 497.220 M | 519.816 M | |
Inventories | 83.155 M | 92.545 M | 95.893 M | 105.355 M | 103.654 M | 104.323 M | 106.590 M | 111.196 M | |
Other Current Assets | 9.708 M | 8.039 M | 8.750 M | 12.214 M | 10.609 M | 12.336 M | 10.690 M | 17.400 M | |
Short Term Investments | 9.708 M | 8.039 M | 8.750 M | 12.214 M | 10.609 M | 12.336 M | 10.690 M | 17.400 M | |
Total Receivables | 131.625 M | 150.410 M | 140.433 M | 165.438 M | 174.713 M | 172.925 M | 178.842 M | 162.079 M | |
Current Cash | 76.911 M | 63.385 M | 56.281 M | 48.228 M | 67.757 M | 161.707 M | 193.078 M | 221.121 M | |
Total Non-current Assets | 443.447 M | 428.935 M | 429.733 M | 415.826 M | 400.471 M | 400.030 M | 392.694 M | 384.606 M | |
Property Plant Equipment | 52.713 M | 43.771 M | 42.830 M | 43.246 M | 43.275 M | 44.371 M | 44.189 M | 44.593 M | |
Other Assets | 2.434 M | 5.762 M | 12.102 M | 11.361 M | 9.228 M | 15.639 M | 16.067 M | 12.072 M | |
Intangible Assets | 281.573 M | 269.593 M | 264.237 M | 251.635 M | 238.791 M | 230.299 M | 219.828 M | 209.009 M | |
Goodwill | 28.188 M | 28.221 M | 28.221 M | 28.221 M | 28.221 M | 28.221 M | 28.221 M | 28.221 M | |
Liabilities and shareholders’ equity | |||||||||
Total Liabilities and shareholders’ equity | 744.846 M | 751.334 M | 739.110 M | 760.087 M | 765.224 M | 859.341 M | 889.914 M | 904.422 M | |
Total liabilities | 398.752 M | 414.376 M | 402.435 M | 421.547 M | 425.742 M | 424.869 M | 435.203 M | 471.673 M | |
Total current liabilities | 79.532 M | 96.312 M | 81.627 M | 99.439 M | 125.825 M | 122.865 M | 134.352 M | 145.477 M | |
Accounts Payable | 22.059 M | 27.641 M | 18.992 M | 29.305 M | 32.687 M | 28.505 M | 34.077 M | 36.683 M | |
Other liabilities | 32.913 M | 31.969 M | 34.926 M | 36.439 M | 14.460 M | 16.760 M | 15.819 M | 41.377 M | |
Current long term debt | 850.000 K | 850.000 K | 850.000 K | 850.000 K | 850.000 K | 850.000 K | 850.000 K | 850.000 K | |
Long term debt | 286.307 M | 286.095 M | 285.882 M | 285.669 M | 285.457 M | 285.244 M | 285.032 M | 284.819 M | |
Other liabilities | 32.913 M | 31.969 M | 34.926 M | 36.439 M | 14.460 M | 16.760 M | 15.819 M | 41.377 M | |
Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Total Shareholder equity | 346.094 M | 336.958 M | 336.675 M | 338.540 M | 339.482 M | 434.472 M | 454.711 M | 432.749 M | |
Common stock | 16.137 M | 16.272 M | 16.303 M | 16.328 M | 16.392 M | 17.688 M | 18.883 M | 19.041 M | |
Retained earnings | -68.300 M | -83.630 M | -92.636 M | -97.286 M | -96.252 M | -90.414 M | -80.880 M | -80.132 M |